Brief: Abbott agrees to DOJ settlement over 2022 infant formula recall
14/09/2026 16:57
BRIEF-Abbott agrees to DOJ settlement over 2022 infant formula recall Sept 14 (Reuters) - Abbott Laboratories ABT.N:
ABBOTT REACHES AGREEMENT WITH DEPARTMENT OF JUSTICE TO RESOLVE CLAIMS RELATING TO 2022 INFANT FORMULA RECALL
ABBOTT - TO PAY $385 MILLION TO RESOLVE CLAIMS; NO FINDING OF FAULT OR LIABILITY
ABBOTT: NO UNOPENED, DISTRIBUTED ABBOTT INFANT FORMULAS HAVE EVER TESTED POSITIVE FOR CRONOBACTER SAKAZAKII
Further company coverage: ABT.N
Recent news on Abbott Laboratories
See all newsBrief: Abbott Announces Availability Of Panbio Covid-19/Flu A&B Self-Test In Canada
Perrigo to sell infant formula business to MeridianMade for up to $175 million
Brief: Abbott Initiates Pivotal Trial For Cephea™ Device, An Innovative Treatment For Mitral Heart Valve Disease
Corrected: German startup NVision shows new path to quantum computing chips in Nature paper
Brief: Abbott Receives FDA Approval For First Device To Treat Leaks After Heart Valve Replacement